- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | Glenmark Pharmaceuticals Ltd slips for fifth straight session | 2 | capitalmarket.com | ||
| 23.04. | Glenmark Pharmaceuticals Ltd spurts 3.28% | 2 | capitalmarket.com | ||
| 09.04. | Glenmark Gets FDA Approval for Bioequivalent Progesterone Vaginal Insert | 6 | Contract Pharma | ||
| 09.04. | Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg | 897 | PR Newswire | ELMWOOD PARK, N.J., April 9, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration... ► Artikel lesen | |
| 09.04. | Glenmark Pharma gets USFDA nod for Progesterone Vaginal Inserts | 5 | capitalmarket.com | ||
| 02.04. | Glenmark goes direct with new US Ryaltris marketing plan as it drops partner model | 5 | FiercePharma | ||
| 01.04. | Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expanding Its Innovative Portfolio | 164 | PR Newswire | RYALTRIS® is Glenmark's first innovative product introduced into the U.S. market
ELMWOOD PARK, N.J., April 1, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc.... ► Artikel lesen | |
| 31.03. | Glenmark Pharmaceuticals Canada Inc. Launches Men's GLN-Minoxidil 5% w/w Topical Aerosol Foam in Canadian Retail | 358 | PR Newswire | GLN-Minoxidil Men's 5% Foam is a topical treatment formulated with 5% minoxidil, a widely used and clinically established ingredient for supporting hair regrowth in men. The fast-drying, unscented aerosol... ► Artikel lesen | |
| 24.03. | Glenmark Pharma may outperform amid market correction; technicals turn positive: Ruchit Jain | 4 | Times of India | ||
| 21.03. | Glenmark Pharma launches GLIPIQ (semaglutide) in India for Type 2 Diabetes at lower cost | 3 | capitalmarket.com | ||
| 19.03. | Glenmark secures USFDA nod for OTC Nasal Spray; launches Generic Milnacipran tablets in US | 3 | capitalmarket.com | ||
| 16.03. | Glenmark Pharma gains as US arm to launch Potassium Phosphates Injection | 2 | capitalmarket.com | ||
| 05.03. | FDA gives Glenmark thumbs up for first 'true' generic version of GSK's asthma inhaler Flovent | 4 | FiercePharma | ||
| 04.03. | Glenmark Gets FDA Nod for Fluticasone Propionate Inhalation Generic | 2 | Contract Pharma | ||
| 04.03. | Glenmark Pharmaceuticals: Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity | 260 | PR Newswire | ELMWOOD PARK, N.J., March 4, 2026 /PRNewswire/ -- Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S.... ► Artikel lesen | |
| 04.03. | Glenmark Pharma secures USFDA nod for Fluticasone Propionate Inhalation Aerosol | 7 | capitalmarket.com | ||
| 04.03. | Glenmark Wins US FDA Approval For Inhalation Therapy Medicine With 180 Day Generic Exclusivity | 4 | The Free Press Journal | ||
| 27.02. | Glenmark Pharma's USA arm to market Sodium Phosphate injection in April 2026 | 3 | capitalmarket.com | ||
| 26.02. | Glenmark Pharmaceuticals Ltd gains for third straight session | 2 | capitalmarket.com | ||
| 22.01. | EQS-News: AcuCort AB: AcuCort schließt kommerzielle Vereinbarung mit Glenmark Pharmaceuticals für Deutschland und fünf weitere europäische Länder | 536 | EQS Group (DE) | EQS-News: AcuCort AB
/ Schlagwort(e): Joint Venture/Produkteinführung
AcuCort schließt kommerzielle Vereinbarung mit Glenmark Pharmaceuticals für Deutschland und fünf weitere... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 1,992 | -1,43 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen | |
| CSPC PHARMA | 0,862 | -1,63 % | CSPC PHARMA (01093): SHARE OPTION SCHEME | ||
| WUXI BIOLOGICS | 3,805 | -0,26 % | Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 2,070 | +2,07 % | FOSUN PHARMA Granted Exclusive Commercialization Option for Alzheimer's Disease Therapy | ||
| GEDEON RICHTER | 34,380 | +1,12 % | Richter Gedeon Plc Reveals Drop In Q1 Profit | ||
| DR REDDYS | 10,900 | +3,81 % | Dr. Reddy's Labs ADR: EPS verfehlt Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | ||
| ASPEN PHARMACARE | 7,150 | -3,38 % | ASPEN PHARMACARE HOLDINGS LIMITED - Dealing in Securities by a Director and Prescribed Officer | ||
| SHANGHAI PHARMACEUTICALS | 1,360 | +3,82 % | Dividendenbekanntmachungen (29.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| LUYE PHARMA | 0,262 | 0,00 % | LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,120 | 0,00 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,530 | -0,93 % | CHINARES PHARMA (03320): ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL COMMERCIAL FOR THE THREE MONTHS ENDED 31 MARCH 2026 IN RELATION ... | ||
| HANSOH PHARMACEUTICAL | 3,898 | 0,00 % | HANSOH PHARMA HS-10541 Tablet Approved for Clinical Trial | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,945 | -3,08 % | SHINEWAY PHARM 1Q26 Revenue RMB624 million, Down 18% YoY | ||
| KALBE FARMA | 0,044 | 0,00 % | KLBF profit rises 13% in 2025, prepares IDR 500 billion buyback: Strong export lifts KLBF's net profit 13% to ... | ||
| BAYER | 37,970 | 0,00 % | Bayer-Bildgebungs-Marker erreicht primäre Endpunkte in Phase-3-Studie | DJ Bayer-Bildgebungs-Marker erreicht primäre Endpunkte in Phase-3-Studie
DOW JONES--Bayer hat mit einem kürzlich zugekauften Bildgebungs-Marker für die Diagnose der kardialen Amyloidose namens... ► Artikel lesen |
Das Unternehmen GLENMARK PHARMACEUTICALS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.